[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vivek Reddy\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":65},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":5},"100634098","represent-pf-registry-100634098",false,"NCT07535268","REPRESENT-PF Registry","Prospective Multicenter Registry on the Clinical Outcomes and Safety of PFA for Atrial Fibrillation in Underrepresented Minorities (REPRESENT-PF Registry)","REPRESENT-PF","Inclusion Criteria:\n\n* All consecutive patients classified as racial or ethnic minorities undergoing ablation using Boston Scientific FDA approved PFA catheters for AF will be included.\n* De novo ablation for symptomatic paroxysmal and persistent AF (Age ≥ 18) (unless it is a repeat for a patient whose index procedure is also in the registry) who are deemed to be candidates for AF ablation by the investigator.\n* Able and willing to participate in baseline and follow up evaluation over the study period\n* Willing and able to provide informed consent, if applicable.\n\nExclusion Criteria:\n\n* Enrolled in an investigational drug or device clinical trial or any other trial with outlined treatment plan\n* Long standing persistent AF (AF \\> 1 year duration)\n* Repeat ablation, unless index ablation procedure was in the REPRESENT-PF registry\n* Any known contra-indication to ablation procedure at the discretion of the investigator","ALL","18 Years",{"count":20,"type":21},275,"ESTIMATED","12 Months","OBSERVATIONAL","This pragmatic, prospective, single-arm, multi-center, observational registry will evaluate the safety and effectiveness of PFA for the treatment of atrial fibrillation in underrepresented minority patients using FDA approved Boston Scientific PFA catheters; all data collected will be standard of care.",[26,27],"Persistent Atrial Fibrillation","Paroxysmal Atrial Fibrillation",[27,26,29],"Pulsed Field Ablation","RECRUITING","2026-04-09",{"date":33,"type":34},"2026-04-17","ACTUAL",{"date":36,"type":34},"2026-03-30",{"date":38,"type":21},"2028-03-01",{"name":40,"class":41},"Vivek Reddy","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100515200","ultra-hfib-redo-ultrasound-based-renal-sympathetic-denervation-vs-control-in-redo-ablation-patients-100515200","NCT05988411","ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients","Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation - Redo Ablation Procedures: A Pilot Study","Inclusion Criteria:\n\n* Age ≥ 18;\n* Planned for a redo AF ablation procedure (paroxysmal or persistent); (prior to randomization, a technically successful AF ablation procedure, defined as successful pulmonary vein isolation, if needed, as well as bidirectional block of any attempted anatomic lesion sets such as cavotricuspid isthmus line, roofline, mitral line and superior vena cava isolation, must have been completed). Note: the clinical recurrences must primarily be atrial fibrillation, and not atrial flutter\u002Ftachycardia (that is, a prospective patient may have a AFL\u002FAT recurrences, but AF must be the dominant recurrent rhythm.)\n* History of hypertension and either:\n\n  * Documented history of SBP≥160 or DBP≥100, or;\n  * Receiving ≥1 antihypertensive medication;\n* Willingness to adhere to study restrictions and comply with all post-procedural follow-up requirements\n\nExclusion Criteria:\n\n* Long-standing persistent AF (\\>12 months); \\>3 prior atrial fibrillation ablations (lifetime); AF ablation within 3 months of enrollment; extensive scar in left atrium.\n* Individual with valvular AF or AF due to a reversible cause\n* Prior treatment with other devices for hypertension including but not limited to ROX Coupler, Mobius stent, and\u002For the CVRx barostimulator device.\n* NYHA class IV congestive heart failure;\n* Individual has renal artery anatomy that is ineligible for treatment (as determined by renal angiography);\n\n  * Main renal artery diameter \\\u003C3mm or \\>8.0 mm\n  * Main renal treatable artery length \\\u003C 20 mm (length may include proximal branches)\n  * Presence of renal artery stenosis of any origin ≥30%\n  * Calcification in renal arteries\n  * Prior renal denervation procedure\n  * Presence of abnormal kidney tumors\n  * Renal artery aneurysm\n  * Pre-existing renal stent or history of renal artery angioplasty\n  * Pre-existing aortic stent or history of aortic aneurysm\n  * Fibromuscular disease of the renal arteries\n  * Iliac\u002Ffemoral artery stenosis precluding insertion of the Paradise Catheter\n* Individual has an estimated glomerular filtration rate (eGFR) of less than 40mL\u002Fmin\u002F1.73m2, using the MDRD calculation;\n* Inability to undergo AF catheter ablation (e.g., presence of a left atrial thrombus, contraindication to all anticoagulation)\n* Individual with known allergy to contrast medium not amendable to treatment.\n* Life expectancy \\\u003C1 year for any medical condition\n* Individual has experienced a myocardial infarction, unstable angina, cerebrovascular accident, or heart failure admission within 3 months of the baseline visit.\n* Documented history of chronic active inflammatory bowel disorders such as Crohn's disease or ulcerative colitis.\n* Female participants who are pregnant or nursing.\n* Individual has known secondary hypertension.\n* Individual has a single functioning kidney (either congenitally or iatrogenically).\n* Individual has a known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or would be unlikely or unable to comply with study follow-up requirements.\n* Patients concurrently enrolled in any other investigational drug or device trial that would interfere with the conduction of this protocol.",{"count":50,"type":21},250,"INTERVENTIONAL",[53],"NA","This is a Prospective, controlled, single-blind, randomized (2:1, Intervention:Control) clinical trial. The purpose of the study is to determine the role of adjunctive renal sympathetic denervation in the prevention of Atrial Fibrillation (AF) recurrence in patients with hypertension scheduled for a redo AF ablation procedure for paroxysmal or persistent AF. Patients will be randomized to either i) AF ablation (Control) or ii) AF ablation + renal sympathetic denervation (Intervention).",[27,26],"2025-12-08",{"date":58,"type":34},"2025-12-15",{"date":60,"type":34},"2023-12-07",{"date":62,"type":21},"2027-12",{"name":40,"class":41},8,""]